FDA grants accelerated approval to INOVIO’s Voceryq for reducing surgery frequency in adults with recurrent respiratory papillomatosis.
|Articles|July 1, 2020
- Pharmaceutical Executive-07-01-2020
- Volume 40
- Issue 7
Pharmaceutical Executive, July 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Will COVID-19 Usher in a New Era in Pharma Marketing?over 6 years ago
Is Drug Production Heading Back to Europe From Abroad?over 6 years ago
Central Focus: Targeting Unmet Need in CNSover 6 years ago
Will the Industry Rise to the Occasion?over 6 years ago
How Oncologists are Coping with COVID-19over 6 years ago
Virtual Hiring of the C-Suiteover 6 years ago
Culture and Compliance: Building a Culture of Business Ethicsover 6 years ago
Fauci: Industry Will ‘Walk Away’ From COVID Price Controlsover 6 years ago
A Sustainable Response to COVID-19over 6 years ago
Enterprise Leadership: Is Compliance Ripe for Disruption?Advertisement
Related to this article
Dr. Jay Lalezari, CytoDyn’s CEO and CMO, discusses his path from HIV clinician to drug developer.
Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Advertisement
Advertisement
Trending on PharmExec
1
What is it Like to Go From Treating Patients Directly to Running a Company?
2
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
3
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
4
Three Levels of Digital Clone Use Cases: Q&A with Hamish Brocklebank
5